PODD:NSD-Insulet Corporation (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 245.35

Change

+8.29 (+3.50)%

Market Cap

USD 19.12B

Volume

1.09M

Analyst Target

USD 241.41
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.46 (-0.65%)

USD 34.53B
MASI Masimo Corporation

+1.07 (+0.65%)

USD 10.18B
BRKR Bruker Corporation

-1.84 (-3.88%)

USD 7.16B
NARI Inari Medical Inc

N/A

USD 4.67B
PRCT Procept Biorobotics Corp

+1.98 (+3.44%)

USD 3.76B
IRTC iRhythm Technologies Inc

+5.91 (+6.03%)

USD 3.53B
QDEL Quidel Corporation

-1.39 (-3.59%)

USD 2.76B
TMDX TransMedics Group Inc

+1.62 (+2.45%)

USD 2.27B
LIVN LivaNova PLC

+2.04 (+5.51%)

USD 2.26B
TNDM Tandem Diabetes Care Inc

-0.27 (-1.49%)

USD 2.11B

ETFs Containing PODD

EDOC:AU BetaShares Digital Health.. 8.02 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 5.14 % 0.00 %

+0.06 (+0%)

USD 2.77M
EDOC:SW Global X Telemedicine & D.. 4.91 % 0.00 %

-0.10 (0%)

N/A
CIB0:XETRA VanEck Bionic Engineering.. 4.85 % 0.00 %

-0.54 (0%)

N/A
CURG:LSE VanEck Genomics and Healt.. 4.57 % 0.00 %

-0.39 (0%)

USD 5.16M
GDOC Goldman Sachs ETF Trust 4.57 % 0.00 %

-0.03 (0%)

USD 0.02B
DDOC:F Global X Telemedicine & D.. 4.51 % 0.00 %

-0.23 (0%)

N/A
FDOC:LSE 4.22 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 4.17 % 0.00 %

+0.10 (+0%)

USD 0.04B
EDOC:LSE Global X Telemedicine & D.. 4.13 % 0.00 %

-0.17 (0%)

USD 3.99M
FDHT:XETRA 4.04 % 0.00 %

N/A

N/A
EDOG:LSE Global X Telemedicine & D.. 4.03 % 0.00 %

-0.15 (0%)

USD 0.36M
FDHT Fidelity Covington Trust .. 3.91 % 0.00 %

-0.04 (0%)

USD 8.72M
CYBG:LSE VanEck Bionic Engineering.. 3.90 % 0.00 %

-0.40 (0%)

N/A
CURE:XETRA VanEck Genomics and Healt.. 3.57 % 0.00 %

-0.54 (0%)

N/A
HLTH:AU VanEck Global Healthcare .. 2.50 % 0.00 %

N/A

USD 0.06B
HEAL:SW iShares Healthcare Innova.. 2.12 % 0.00 %

-0.07 (0%)

USD 1.05B
ZHU:CA BMO Equal Weight US Healt.. 1.77 % 0.00 %

-0.43 (0%)

CAD 0.01B
SLIM 0.00 % 0.50 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

-1.15 (0%)

CAD 0.22B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-15.63 (0%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.18 (0%)

N/A
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

-0.21 (0%)

USD 1.14B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.07 (0%)

N/A
BKMC BNY Mellon US Mid Cap Cor.. 0.00 % 0.00 %

-0.41 (0%)

USD 0.54B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.23 (0%)

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

-0.13 (0%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.04 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.02% 64% D 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.02% 64% D 50% F
Trailing 12 Months  
Capital Gain 34.93% 88% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.93% 88% B+ 86% B+
Trailing 5 Years  
Capital Gain 42.55% 83% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.55% 83% B 53% F
Average Annual (5 Year Horizon)  
Capital Gain 5.00% 52% F 53% F
Dividend Return 5.00% 52% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.95% 79% B- 57% F
Risk Adjusted Return 15.18% 64% D 47% F
Market Capitalization 19.12B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.